Imiquimod NEW
| Price | $37 | $50 | $68 |
| Package | 50mg | 100mg | 200mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-04-30 |
Product Details
| Product Name: Imiquimod | CAS No.: 99011-02-6 |
| Purity: 99.66% | Supply Ability: 10g |
| Release date: 2025/04/30 |
Product Introduction
Bioactivity
| Name | Imiquimod |
| Description | Imiquimod (R 837) is an immune response modifier that acts as a toll-like receptor 7 agonist. |
| In vivo | In animal models, imiquimod stimulates the innate immune response by increasing NK cell activity, activating macrophages to secrete cytokines and nitric oxide, and inducing proliferation and differentiation of B lymphocytes. Imiquimod stimulates the innate immune response through induction, synthesis, and release of cytokines, including interferon-a (IFN-α), interleukin (IL)-6, and tumour necrosis factor (TNF)-α[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : Insoluble DMSO : 1 mg/mL (4.16 mM), Sonication and heating are recommended. |
| Keywords | warts | vulvar | Toll-like Receptor (TLR) | TLR8 | TLR7 | TLR | squamous | SARS-CoV | SARSCoV | SARS coronavirus | S26308 | S 26308 | R-837 | R837 | papillomavirus | nongenital | neoplasia | molluscum | keratosis | intraepithelial | Inhibitor | inhibit | infection | Imiquimod | human | HSV | Herpes simplex virus | disease | contagiosum | cell | carcinoma | Bowen's | basal ,cell | Autophagy | actinic |
| Inhibitors Related | Stavudine | Xylitol | Aceglutamide | Sodium 4-phenylbutyrate | Hydroxychloroquine | Guanidine hydrochloride | Taurine | Valproic Acid | Curcumin | Paeonol | Naringin | Gefitinib |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Viral Compound Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $37.00/50mg |
VIP2Y
|
TargetMol Chemicals Inc.
|
2025-10-27 | |
| $37.00/50mg |
VIP6Y
|
TargetMol Chemicals Inc.
|
2025-10-27 | |
| $0.00/25KG |
VIP6Y
|
Sichuan Zhuoyu Yantang Technology Co., Ltd.
|
2025-08-28 | |
| $5.00/1KG |
VIP1Y
|
Wuhan JiyunZen Tech Co., Ltd.
|
2025-05-07 | |
| $0.00/1kg |
VIP2Y
|
Shaanxi Xianhe Biotech Co., Ltd
|
2025-04-30 | |
| $/ |
VIP5Y
|
RongNa Biotechnology Co.,Ltd
|
2025-04-29 | |
| $80.00/1KG |
Shandong Xuhuang New material CoLTD
|
2025-02-21 | ||
| $10.00/1KG |
VIP7Y
|
Hebei Chuanghai Biotechnology Co., Ltd
|
2024-11-29 | |
| $1000.00/1ton |
VIP2Y
|
HEBEI SHENGSUAN CHEMICAL INDUSTRY CO.,LTD
|
2024-08-14 | |
| $0.10/1KG |
VIP6Y
|
Shaanxi Dideu Medichem Co. Ltd
|
2024-07-05 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY